INHIBIDORES CONTRA EL FACTOR VIII DE COAGULACIÓN EN

INHIBIDORES CONTRA EL FACTOR VIII DE COAGULACIÓN EN LA HEMOFILIA TIPO A
Coagulation Factor VIII Inhibitors in hemophilia type A
+Carlos A. Medina
*Rhina Z. Pineda
RESUMEN
/RVLQKLELGRUHVVRQXQSUREOHPDJUDYHTXHSXHGH
RFXUULUFXDQGRXQDSHUVRQDFRQKHPRÀOLDSUHVHQWD
XQD UHVSXHVWD LQPXQROyJLFD DO WUDWDPLHQWR FRQ
FRQFHQWUDGRV GH IDFWRU 9,,, GH FRDJXODFLyQ (O
VLVWHPD LQPXQROyJLFR SURWHJH DO FXHUSR FRQWUD
JpUPHQHV \ YLUXV GDxLQRV SHUR DOJXQDV YHFHV HO
VLVWHPDLQPXQROyJLFRGHXQDSHUVRQDUHDFFLRQDD
ODV SURWHtQDV GH ORV FRQFHQWUDGRV GH IDFWRU FRPR
VL IXHUDQ VXVWDQFLDV DMHQDV \D TXH HO FXHUSR
QR ODV UHFRQRFH &XDQGR HVWR RFXUUH VH IRUPDQ
LQKLELGRUHV WDPELpQ OODPDGRV DQWLFXHUSRV HQ OD
VDQJUH SDUD DWDFDU D ODV SURWHtQDV GH IDFWRU 9,,,
(VWRLPSLGHDORVFRQFHQWUDGRVGHIDFWRUFRUUHJLU
HOSUREOHPDKHPRUUiJLFR
Palabras Clave: +HPRÀOLD VHYHUD WLSR $
WROHUDQFLDDOIDFWRU9,,,FRPSLODFLyQHQKHPRÀOLD
WLSR$
ABSTRACT
3DWLHQWZLWK7\SH$+HPRSKLOLDSUHVHQWLQKLELWRUV
ZKLFK DUH VHULRXV PHGLFDO SUREOHPV ZKHQ WKH\
UHDFW LQ DQ LPPXQRORJLFDO UHVSRQVH WR WUHDWPHQW
ZLWK FRDJXODWLRQ FRQFHQWUDWLRQV RI )DFWRU 9,,,
7KH ,PPXQH 6\VWHP SURWHFWV WKH ERG\ DJDLQVW
JHUPV YLUXVHV DQG PDQ\ RWKHU IRUHLJQ DJHQWV
+HPRSKLOLDFVGHYHORSDQLPPXQRORJLFDOUHVSRQVH
LQYROYLQJ WKH VHFUHWLRQ RI LQKLELWRUV DOVR NQRZQ
DV DQWLERGLHV LQWR WKH EORRG ZKLFK LQKLELWV
FRDJXODWLRQ IURP )DFWRU 9,,, SURWHLQ WKLV GXH
”Mario A. Rush, José Reyes
WR WKH IDFW WKDW WKH ERG\ GRHV QRW UHFRJQL]H WKLV
SURWHLQ7KHGHYHORSPHQWRIWKHVHHYHQWVSUHYHQWV
WKH )DFWRU 9,,, FRQFHQWUDWLRQV WR FRUUHFW WKH
KHPRUUKDJLFSUREOHP
Key Words: 6HYHUH W\SH $ KHPRSKLOLD
WROHUDQFHWRIDFWRU9,,,FRPSOLFDWLRQVLQW\SH$
KHPRSKLOLD
CASO CLÍNICO
3DFLHQWH PDVFXOLQR GH DxRV FRQ KLVWRULD
GH KHPRÀOLD GLDJQRVWLFDGD DO PHV GH QDFLGR
SUHVHQWDQGR FXDGURV UHSHWLGRV GH KHPRUUDJLD
HQ ODV DUWLFXODFLRQHV PD\RUHV SULQFLSDOPHQWH D
QLYHOGHODVURGLOODV\ORVFRGRVODVFXDOHVIXHURQ
GHIRUPDQGR SURJUHVLYDPHQWH VXV H[WUHPLGDGHV H
LQFDSDFLWDQGRHOPRYLPLHQWRItVLFR&RQWURODGDFRQ
)DFWRU9,,,UHFRPELQDQWHGXUDQWHDxRV+DFH
DxRVVHREVHUYyTXH\DQRUHVSRQGtDDODUHVWLWXFLyQ
GHOIDFWRUHQODVGRVLVWHUDSpXWLFDV\SUHVHQWyXQD
FULVLV GH DQDÀOD[LD GHVSXpV GH OD DSOLFDFLyQ GH
VX WUDWDPLHQWR KDELWXDO 6H OH UHDOL]DURQ DQiOLVLV
GH%HWKHVGDORVFXDOHVUHSRUWDURQODSUHVHQFLDGH
LQKLELGRUHV FRQWUD )DFWRU 9,,, VLHQGR WUDWDGR D
SDUWLUGHHQWRQFHVFRQIDFWRU9,,DUHFRPELQDQWHHO
FXDOQRPHMRUyVXFRQGLFLyQGHVDOXG
$ SDUWLU GH HQWRQFHV HO SDFLHQWH UHÀHUH XQD
GLVPLQXFLyQGHODFDOLGDGGHYLGD\DTXHODPD\RU
SDUWH GH VX WLHPSR SDVD LQWHUQR HQ HO +RVSLWDO
(VFXHOD SRU SUHVHQWDU KHPRUUDJLDV PDVLYDV \
HVSRQWiQHDV HVSHFLDOPHQWH HQ URGLOODV FRGRV \
KRPEURVDFRPSDxDGDGHGRORULQFDSDFLWDQWH+DFH
+ Gineco-Obstetra, Profesor Titular IV, Facultad de Ciencias Médicas de la UNAH.
* Estudiante de VI año, Carrera de Medicina de la UNAH. Miembro de ASOCEMH-UNAH.
” Estudiantes de III año, Carrera de Medicina de la UNAH. Miembros de ASOCEMH-UNAH
Rev. Fac. Cienc. Méd. Julio - Diciembre 2010
Inhibidores Contra el Factor VIII de Coagulación en la Hemofilia Tipo A
XQDxRSUHVHQWDFHIDOHDKRORHQFHIiOLFDFRQWLQXDGH
WLSRSXOViWLOGHSUHGRPLQLRPDWXWLQRUHDOL]iQGRVHOH
XQD 7RPRJUDItD$[LDO &RPSXWDUL]DGD 7$& TXH
PRVWUyODSUHVHQFLDGHP~OWLSOHVPLFURLQIDUWRVHQ
HOOyEXORRFFLSLWDOL]TXLHUGRGHOFHUHEUR
/RVQLYHOHVGH7LHPSRGH7URPERSODVWLQD3DUFLDO
773 SHUPDQHFHQ HOHYDGRV DXQ GHVSXpV GH OD
DSOLFDFLyQGHO)DFWRU9,,DUHFRPELQDQWH
Antecedentes familiares patológicos:+HUPDQR
PHQRU FRQ GLDJQyVWLFR GH KHPRÀOLD PXULy SRU
KHPRUUDJLDPDVLYDXQVREULQRKHPRItOLFRPXULy
SRU DSHQGLFLWLV FRPSOLFDGD DPERV FDVRV VLQ
DQWHFHGHQWHV GH KDEHU GHVDUUROODGR LQKLELGRUHV
1LHJD FDVRV IDPLOLDUHV GH KHPRÀOLD SUHFHGLGRV D
pO
KDEHUVLGR´YLVWDµDQWHVSRUHOVLVWHPDLQPXQH\
SODQWHDXQUHWRWHUDSpXWLFRPX\GLItFLOGHVXSHUDU
(O GHVDUUROOR GH LQKLELGRUHV UHSUHVHQWD OD
FRPSOLFDFLyQ PiV VHYHUD HQ HO WUDWDPLHQWR GHO
HQIHUPRKHPRItOLFR
/DV KHPRUUDJLDV VRQ PX\ GLItFLOHV GH FRQWURODU
HQ XQD SHUVRQD FRQ KHPRÀOLD TXH SUHVHQWD
LQKLELGRUHV8QDSHUVRQDFRQLQKLELGRUHVHQIUHQWD
PiV KHPRUUDJLDV \ GRORU SRUTXH HO WUDWDPLHQWR
FRQ FRQFHQWUDFLRQHV GH IDFWRU QR IXQFLRQD 6t OD
KHPRUUDJLD HQ P~VFXORV \ DUWLFXODFLRQHV QR HV
FRQWURODGDHVSUREDEOHTXHKD\DGDxRVDUWLFXODUHV
(O GHVDUUROOR GH DQWLFXHUSRV LQKLELGRUHV
FRQGLFLRQDQRVyORXQDGLVPLQXFLyQGHODFDOLGDG
GHYLGDGHORVSDFLHQWHVVLQRTXHWDPELpQWLHQHQ
LPSRUWDQWHVFRQVHFXHQFLDVVRFLRHFRQyPLFDVGDGR
HOLQFUHPHQWRHQHOFRVWRGHOWUDWDPLHQWR
INTRODUCCIÓN
/D +HPRÀOLD $ HV XQD HQIHUPHGDG KHUHGLWDULD
DVRFLDGD FRQ KHPRUUDJLDV JUDYHV HVSRQWiQHDV R
SURYRFDGDV6HGHEHDXQDUHGXFFLyQHQODFDQWLGDGR
DODDFWLYLGDGGH)DFWRU9,,,/DKHPRÀOLDVHKHUHGD
FRQFDUiFWHUUHFHVLYROLJDGRDOFURPRVRPD;ORV
VXMHWRVPDVFXOLQRVVRQORVDIHFWDGRVFOtQLFDPHQWH
SRUTXHODVPXMHUHVVRQSRUWDGRUDVGHOJHQPXWDGR
SRUORJHQHUDOVRQDVLQWRPiWLFDV$IHFWDDGHFDGD
YDURQHVHQWRGRHOPXQGR
$SUR[LPDGDPHQWH HO GH ORV SDFLHQWHV QR
WLHQHQKLVWRULDIDPLOLDUVXHQIHUPHGDGHVWiFDXVDGD
SRVLEOHPHQWH SRU PXWDFLRQHV QXHYDV /D
KHPRÀOLD$ H[KLEH XQD DPSOLD JDPD GH YDULHGDG
FOtQLFDODJUDYHGDGGHpVWDGHSHQGHGHODFDQWLGDG
GHIDFWRUGHFRDJXODFLyQTXHIDOWDHQODVDQJUHGH
XQDSHUVRQD/RVLQGLYLGXRVFRQPHQRVGHGH
ODDFWLYLGDGQRUPDOGHVDUUROODQHQIHUPHGDGJUDYH
ORVQLYHOHVHQWUH\VHDVRFLDQFRQHQIHUPHGDG
PRGHUDGD\ORVQLYHOHVHQWUH\GHDFWLYLGDG
H[SHULPHQWDQHQIHUPHGDGOHYH$OUHGHGRUGHO
GH ORV SDFLHQWHV FRQ )DFWRU 9,,, EDMR R DXVHQWH
GHVDUUROODQ DQWLFXHUSRV LQKLELGRUHV TXH VH XQHQ
DOIDFWRU9,,,\ORLQKLEHQSRVLEOHPHQWHGHELGRD
TXH OD SURWHtQD HV SHUFLELGD FRPR H[WUDxD DO QR
Epidemiologia
'H DFXHUGR FRQ OD )HGHUDFLyQ 0XQGLDO GH OD
+HPRÀOLDHQHODxRKDEtDSDFLHQWHV
FRQ KHPRÀOLD UHJLVWUDGRV 6H HVWLPD TXH HQWUH
\ SDFLHQWHV KHPRItOLFRV HQ /DWLQR
$PpULFD WLHQHQ LQKLELGRUHV (O GHVDUUROOR GH
LQKLELGRUHVVXFHGHHQXQ²GHORVSDFLHQWHV
FRQKHPRÀOLD$
8QDPD\RULQFLGHQFLDGH+HPRÀOLD$VHSUHVHQWD
HQSDFLHQWHVFRQXQKLVWRULDOIDPLOLDUGHDQWLFXHUSRV
FRQWUDHO)DFWRU9,,,/DVSHUVRQDVGHDVFHQGHQFLD
DIULFDQDFRQ+HPRÀOLD$WLHQHQPiVSRVLELOLGDGHV
GHGHVDUUROODULQKLELGRUHVGHO)DFWRU9,,,TXHODV
SHUVRQDVFDXFiVLFDV
Etiología
(Q UHODFLyQ FRQ OD HWLRSDWRJHQLD PXFKR VH
KD HVSHFXODGR DFHUFD GH FXiOHV VRQ ODV FDXVDV
TXH FRQGLFLRQDQ OD DSDULFLyQ GH DQWLFXHUSRV
LQKLELGRUHV 6H KDQ LPSOLFDGR IDFWRUHV JHQpWLFRV
IXQGDPHQWDOPHQWH UHODFLRQDGRV FRQ HO WLSR
GHDOWHUDFLyQJHQpWLFDTXHFRQGLFLRQDODKHPRÀOLD
HOVLVWHPD$QWtJHQR+XPDQR/HXFRFLWDULR+/$
\ HO WLSR GH IDFWRU XWLOL]DGR HQ OD WHUDSpXWLFD
VXVWLWXWLYD /RV SDFLHQWHV TXH VH VRPHWHQ D
Rev. Fac. Cienc. Méd. Julio - Diciembre 2010
Inhibidores Contra el Factor VIII de Coagulación en la Hemofilia Tipo A
OD WHUDSLD GH UHHPSOD]DPLHQWR HQ XQ SURGXFHQDQWLFXHUSRVQHXWUDOL]DQWHV(OSDSHO
GHVHPSHxDGR SRU HO VLVWHPD LQPXQH D OD KRUD GH
GHVDUUROODUDQWLFXHUSRVHVIXQGDPHQWDOQRVyORSRU
UHJXODUORVIHQyPHQRVGHWROHUDQFLDLQPXQHIUHQWH
DO )DFWRU 9,,, VLQR SRU FRQIRUPDU OD PDTXLQDULD
HIHFWRUD GHO RUJDQLVPR GHÀFLHQWH GH IDFWRU IUHQWH
ODDGPLQLVWUDFLyQH[yJHQDGHSURWHtQD
Fisiopatología
Respuesta inmune al Factor VIII
(Q OD KHPRÀOLD FXDQGR QR HVWi OD SURWHtQD GHO
)DFWRU 9,,, SDUD FUHDU WROHUDQFLD OD LQIXVLyQ
GH FRQFHQWUDGRV GH )9,,, JHQHUD OD UHVSXHVWD
LQPXQLWDULD OD FXDO VH LQLFLD GHVGH ODV FpOXODV
SUHVHQWDGRUDVGHDQWtJHQR&3$TXHLQWHUDFW~DFRQ
ORVOLQIRFLWRV7\HVWRVDVXYH]FRQORVOLQIRFLWRV
% (VWRV ~OWLPRV KDQ XQLGR \ HQGRFLWDGR ORV
DQWtJHQRVSURWHLFR\SRVWHULRUPHQWHSUHVHQWDQORV
SpSWLGRVGHULYDGRVGHHVWHDQWtJHQRDORVOLQIRFLWRV
7 FRRSHUDGRUHV \ D OD YH] HVWRV HVWLPXODQ D ORV
OLQIRFLWRV%SDUDTXHVLQWHWLFHQDQWLFXHUSRVIUHQWH
D HVD SURWHtQD ([LVWHQ PXFKDV HYLGHQFLDV
TXH FRQÀUPDQ TXH DO LJXDO TXH HQ OD PD\RUtD GH
ORV DQWtJHQRV SURWHLFRV OD UHVSXHVWD KXPRUDO TXH
VH SURGXFH IUHQWH DO )DFWRU 9,,, HV OLQIRFLWR 7
GHSHQGLHQWH
/DUHVSXHVWDLQPXQHIUHQWHDXQDQWtJHQRSHSWtGLFR
H[WUDFHOXODUFRPRHVHO)DFWRU9,,,RFXUUHDWUDYpV
GH XQD VHULH GH LQWHUDFFLRQHV HQWUH ODV FpOXODV
SUHVHQWDGRUDV GH DQWtJHQD &3$ ORV OLQIRFLWRV7
&'\ORVOLQIRFLWRV%
(O HYHQWR LQLFLDO HQ HVWD FDVFDGD FHOXODU HV HO
FRQWDFWRHQWUHHO)DFWRU9,,,\ODV&3$7UDVHVWD
XQLyQ VH SURGXFH XQD HQGRFLWRVLV GHO )DFWRU9,,,
D WUDYpV GH YHVtFXODV SURGXFLpQGRVH OD XQLyQ GH
GHWHUPLQDGDVVHFXHQFLDVSHSWtGLFDVGHO)DFWRU9,,,
FRQPROpFXODVGHFODVH,,GHOFRPSOHMRPD\RUGH
KLVWRFRPSDWLELOLGDG&0+/DXQLyQGHSpSWLGRV
SURFHGHQWHVGHO)DFWRU9,,,DPROpFXODVGHFODVH,,
GHO&0+HVHVSHFLÀFRGHODVHFXHQFLDSHSWtGLFD\
GHSHQGLHQWHGHODLQWHUDFFLyQHQWUHORVDPLQRiFLGRV
GHO)DFWRU9,,,\ORVDPLQRiFLGRVTXHFRQIRUPDQ
OD ]RQD GH XQLyQ D SpSWLGRV GH ODV PROpFXODV GH
FODVH,,GHO&0+
(O UHFRQRFLPLHQWR GH HVWH FRPSOHMR IRUPDGR
SRU DQWtJHQRV SHSWtGLFRV GHO )9,,, \ PROpFXODV
FODVH ,, GHO &0+ VH UHDOL]D D WUDYpV GHO UHFHSWRU
GH OLQIRFLWRV 7 7&5 \ &' (VWD XQLyQ GHO
UHFHSWRU DO DQWtJHQR QR HV FDSD] GH SURGXFLU
DFWLYDFLyQ OLQIRFLWDULD GH IRUPD DLVODGD VLQR TXH
QHFHVLWD GH OD SDUWLFLSDFLyQ GH ODV GHQRPLQDGDV
YtDV FRHVWLPXODGRUDV %iVLFDPHQWH HVWDV YtDV
FRQVWLWX\HQFRPSOHMRVOLJDQGR²UHFHSWRUQHFHVDULRV
SDUDODDFWLYDFLyQ\UHJXODFLyQOLQIRFLWDULD
)LQDOPHQWH GH OD LQWHUDFFLyQ GH WRGDV ODV VXE
SREODFLRQHVOLQIRFLWDULDVVHFRQVLJXHODSURGXFFLyQ
GH DQWLFXHUSRV IUHQWH DO )DFWRU 9,,, JUDFLDV D OD
GLIHUHQFLDFLyQ ÀQDO GH ORV OLQIRFLWRV % D FpOXODV
SODVPiWLFDV ODV FXDOHV DGTXLHUHQ OD FDSDFLGDG
GH SURGXFLU \ VHFUHWDU JUDQGHV FDQWLGDGHV GH
DQWLFXHUSR (VWRV DQWLFXHUSRV LQKLELWRULRV IUHQWH
DO IDFWRU 9,,, VRQ GH FDUDFWHUtVWLFDV SROLFORQDOHV
JHQHUDOPHQWH,J*\HQDOJXQRVFDVRV,J*
Aspectos generales de los inhibidores
8QLQKLELGRUHVXQWLSRGHDQWLFXHUSR/DIXQFLyQGH
ORVDQWLFXHUSRVHQHORUJDQLVPRHVWUDWDUGHGHVWUXLU
VXVWDQFLDVTXHQRUHFRQRFHQ(ORUJDQLVPRGHXQD
SHUVRQD FRQ +HPRÀOLD$ SXHGH FUHDU LQKLELGRUHV
GLULJLGRV FRQWUD HO )DFWRU 9,,, GHVSXpV GH OD
DGPLQLVWUDFLyQGHOWUDWDPLHQWRSDUDUHHPSOD]DUHO
IDFWRUFDUHQWH(OGHODVSHUVRQDTXHSUHVHQWDQ
LQKLELGRUHV OR KDFHQ GHQWUR GH ODV SULPHUDV H[SRVLFLRQHVDORVFRQFHQWUDGRVGHIDFWRU VLHQGR
HO PRPHQWR GH PD\RU ULHVJR HO SHULRGR HQWUH ORV
SULPHURV\WUDWDPLHQWRV(VWRTXLHUHGHFLU
TXH ORV LQKLELGRUHV VH SUHVHQWDQ SULQFLSDOPHQWH
HQ QLxRV FRQ KHPRÀOLD VHYHUD DXQTXH WDPELpQ
SXHGHQ SUHVHQWDUVH HQ HWDSDV SRVWHULRUHV GH OD
YLGDHQSHUVRQDVFRQKHPRÀOLDOHYHRPRGHUDGD
GHVSXpVGHUHFLELUWUDWDPLHQWR
(VWDFRPSOLFDFLyQVHSUHVHQWDFRQPD\RUIUHFXHQFLD
HQSDFLHQWHVFRQKHPRÀOLDJUDYHTXHHQSHUVRQDV
FRQKHPRÀOLDOHYHRPRGHUDGD\HVPiVFRP~QHQ
Rev. Fac. Cienc. Méd. Julio - Diciembre 2010
Inhibidores Contra el Factor VIII de Coagulación en la Hemofilia Tipo A
OD+HPRÀOLD$DTXHHQODKHPRÀOLD%
(O DQWLFXHUSR VH DGKLHUH DO )DFWRU 9,,, \ OR
QHXWUDOL]DRLQKLEHVXFDSDFLGDGSDUDGHWHQHUXQD
KHPRUUDJLD &XDQGR VH GHWHFWD XQ DQWLFXHUSR
SRU OR JHQHUDO VH FODVLÀFD FRPR GH ´DOWD R EDMD
UHVSXHVWDµ GHSHQGLHQGR GH OD IRUPD HQ OD TXH
HVWLPXOHDOVLVWHPDLQPXQHGHXQDSHUVRQDGHVSXpV
GHUHSHWLGDVH[SRVLFLRQHVDO)DFWRU9,,,
(Q OD +HPRÀOLD$ ORV SDFLHQWHV FRQ PXWDFLRQHV
TXH WUXQFDQ R LPSLGHQ OD SURGXFFLyQ GHO )DFWRU
9,,, LQYHUVLyQ GH LQWUyQ GHOHFLRQHV JUDQGHV
PXWDFLRQHVVLQVHQWLGRWLHQHQPD\RUIUHFXHQFLDGH
GHVDUUROODULQKLELGRUHVTXHDTXHOORVFRQGHOHFLRQHV
Sintomatología en una persona que ha
desarrollado inhibidores
6HVRVSHFKDODSUHVHQFLDGHLQKLELGRUHVFXDQGROD
SHUVRQDHOIDPLOLDURHOSHUVRQDOPpGLFRQRWDQTXH
HOWUDWDPLHQWRHVPHQRVHÀFD]GHORTXHVROtDVHU
+DOOD]JRVFOtQLFRV
/DKHPRUUDJLDQRVHFRQWURODDGHFXDGDPHQWH
FRQODGRVLVXVXDOGHFRQFHQWUDGRVGHIDFWRU
(O WUDWDPLHQWR QRUPDO SDUHFH VHU FDGD YH]
PHQRVHÀFD]
/D KHPRUUDJLD HV FDGD YH] PiV GLItFLO
GH FRQWURODU \D TXH XQD SHUVRQD FRQ
KHPRÀOLD TXH KD GHVDUUROODGR LQKLELGRUHV QR
PHMRUDUiGHVSXpVGHOWUDWDPLHQWRQRUPDOFRQ
FRQFHQWUDGRVGHIDFWRU
Diagnóstico
&RQ IUHFXHQFLD VH VRVSHFKD OD SUHVHQFLD GH
LQKLELGRUHVGXUDQWHXQDSUXHEDGHVDQJUHGHUXWLQD
FRQRFLGDFRPRHQVD\RGHWLHPSRGHWURPERSODVWLQD
SDUFLDODFWLYDGR773D/DSUXHEDGH773DPLGH
HOWLHPSRTXHWDUGDODVDQJUHHQFRDJXODU&XDQGR
KD\ LQKLELGRUHV SUHVHQWHV OD VDQJUH WDUGD HQ
FRDJXODURQRFRDJXODFRPSOHWDPHQWHDXQGHVSXpV
GHKDEHUVHPH]FODGRFRQSODVPDQRUPDO
(Q XQ SDFLHQWH FRQ GLDJQyVWLFR GH KHPRÀOLD TXH
QRUHVSRQGHDOWUDWDPLHQWRVXVWLWXWLYRFRQODVGRVLV
DGHFXDGDV VH UHDOL]DQ ORV VLJXLHQWHV PpWRGRV GH
GHWHFFLyQGHLQKLELGRUHV
'HWHUPLQDFLyQSRUXQLGDGHV2[IRUG
3UXHEDVFOiVLFDVGH%HWKHVGD
'HWHUPLQDFLyQGH1LMPHJHQ
7HFLQDVGH(OLVD
(O HQVD\R %HWKHVGD HV HO PpWRGR HVWiQGDU
UHFRPHQGDGR SDUD OD PHGLFLyQ GH ORV WtWXORV GH
LQKLELGRUHVGHO)9,,,
Con la prueba de Bethesda los inhibidores se
clasifican en:
/RV GH EDMD UHVSXHVWD SRVHHQ QLYHOHV GH
LQKLELGRUHV D 8QLGDGHV %HWKHVGD PO %8
1R GHVDUUROODQ XQ LQFUHPHQWR HQ ORV QLYHOHV GH
LQKLELGRUHVOXHJRGHVXEVLJXLHQWHVH[SRVLFLRQHVD
)9,,,
/RVGHDOWDUHVSXHVWDSRVHHQWtWXORVGHLQKLELGRUHV
!%8PORELHQVLORVQLYHOHVKDEtDQGHVFHQGLGR
EDMRHVWDFLIUDORVWtWXORVVXELUtDQD!%8PO
OXHJRGHODUHH[SRVLFLyQD)9,,,
Tratamiento
(O HVWXGLR GH OD SUHVHQFLD GHO LQKLELGRU FRQWUD OD
PROpFXOD GHO IDFWRU 9,,, FRQVWLWX\H RWUR GH ORV
DYDQFHV HQ HO WUDWDPLHQWR GH ODV SHUVRQDV FRQ
KHPRÀOLDTXHKDQGHVDUUROODGRLQKLELGRUHVFRQWUD
IDFWRU9,,,
Tratamiento de sangrado leve y moderado
en pacientes con hemofilia A e inhibidores de
baja respuesta:
$OWDV 'RVLV GH )9,,, GH ² ,8NJ GH SHVR
FRUSRUDOHQERORFDGDDKRUDV6LQRKXELHUH
UHVSXHVWD D ODV DOWDV GRVLV GH )9,,, VDQJUDGR
SHUVLVWHQWH GHELGR D LPSRVLELOLGDG GH PDQWHQHU
QLYHOHV DGHFXDGRV GH )9,,, $XPHQWDU GRVLV
DQWHULRU R FDPELDU DO WUDWDPLHQWR SDUD SDFLHQWHV
FRQDOWDUHVSXHVWD
Rev. Fac. Cienc. Méd. Julio - Diciembre 2010
Inhibidores Contra el Factor VIII de Coagulación en la Hemofilia Tipo A
Tratamiento de sangrado leve y moderado
en pacientes con hemofilia A e inhibidores de
alta respuesta
6H XWLOL]D IDFWRU 9,, DFWLYDGR UHFRPELQDGR
U)9,,D \ HO FRQFHQWUDGR GH FRPSOHMR GH
SURWURPELQD DFWLYDGR D3&& FRQVWLWX\HQ ORV
DJHQWHVSUHIHULGRVSDUDHOVDQJUDGROHYH\PRGHUDGR
HQSDFLHQWHVGHDOWDUHVSXHVWD
(O IDFWRU 9,,D UHFRPELQDQWH KXPDQR VH
FRQVLGHUD DFWXDOPHQWH HO WUDWDPLHQWR GH HOHFFLyQ
HQORVSDFLHQWHVKHPRItOLFRVFRQLQKLELGRUHVGHDOWD
UHVSXHVWDSRUTXHQRJHQHUDUHVSXHVWDDQDPQpVLFDGH
ORVWtWXORVGHOLQKLELGRUFRQWUDHO)9,,,WLHQHPHQRU
ULHVJRGHWURPERVLV\VHHYLWDHOULHVJRHPSOHDUXQ
SURGXFWRGHRWUDHVSHFLHFRPRHQHOFRQFHQWUDGR
GH IDFWRU 9,,, SRUFLQR 6LQ HPEUDJR XQR GH ORV
PD\RUHVSUREOHPDVGHVXXVRHVVXDOWRFRVWR
(QDOJXQRVSDtVHVVHKDHPSOHDGRHO)9,,,SRUFLQR
SDUD HO SDFLHQWH FRQ DOWD UHVSXHVWD $XQTXH
VH KD REVHUYDGR XQ PHQRU ULHVJR GH UHVSXHVWD
DQDPQpVLFDGHORVWtWXORVGHDQWLFXHUSRVFRQWUDHO
IDFWRU9,,,SRUFLQRGHEHUiYLJLODUVHODSRVLELOLGDG
GHUHDFFLRQHVDQDÀOiFWLFDV
3ODVPDIHUHVLV /D SODVPDIHUHVLV HV XQ
SURFHGLPLHQWR TXH HOLPLQD ORV LQKLELGRUHV GHO
WRUUHQWHVDQJXtQHRGHXQDSHUVRQD*HQHUDOPHQWH
VH XWLOL]D FXDQGR VH QHFHVLWD UHGXFLU UiSLGDPHQWH
HO WtWXOR GHO LQKLELGRU SRU HMHPSOR DQWHV GH XQD
FLUXJtDPD\RURHQFDVRVGHKHPRUUDJLDJUDYHTXH
QRVRQELHQFRQWURODGRVFRQDJHQWHVGHGHVYtR
3DUD OD HUUDGLFDFLyQ GHO DQWLFXHUSR LQKLELWRULR OD
LQPXQRVXSUHVLyQQRHVHÀFD]/DLQGXFFLyQGHOD
WROHUDQFLDLQPXQROyJLFD,7,VHSUHVHQWDFRPR
OD PHMRU RSFLyQ D ODUJR SOD]R SDUD SDFLHQWHV FRQ
LQKLELGRUHV GH DOWD UHVSXHVWD (VWH SURFHGLPLHQWR
GHVDUUROODGRHQVHEDVDHQODDGPLQLVWUDFLyQ
GH GRVLV HOHYDGDV GH FRQFHQWUDQGR OLRÀOL]DGR
GH )9,,, R GH FRPSOHMR SURWURPEtQLFR /D
,7, FRQVLVWH HQ DGPLQLVWUDU GRVLV IUHFXHQWHV GH
FRQFHQWUDGRGHOIDFWRUDODSHUVRQDFRQLQKLELGRUHV
GXUDQWHYDULRVPHVHVRDOJXQDVYHFHVDODxRDÀQ
GH HQWUHQDU DO FXHUSR D UHFRQRFHU HO SURGXFWR GH
WUDWDPLHQWR 'HVSXpV GH VHLV PHVHV D XQ DxR ORV
WtWXORV GH DQWLFXHUSRV FRQWUD HO )9,,, VH UHGXFHQ
FRQVLGHUDEOHPHQWHKDVWDOOHJDUDFHUR
([LVWHQ RWURV SURFHGLPLHQWRV SDUD OD WROHUDQFLD
LQPXQROyJLFDFRPRHOHPSOHRGHODLQPXQRJOREXOLQD
* OD LQPXQRDGVRUFLRQ LQPXQRVXSUHVLyQ
FRQ FLFORIRVIDPLGD SUHGQLVRQD ERORV GH
PHWLOSUHGQLVRORQD R OD FRPELQDFLyQ GH WRGRV HVWRV
SURFHGLPLHQWRV $FWXDOPHQWH VH HVWi WUDEDMDQGR
HQ HO WUDWDPLHQWR FRQ WHUDSLD JpQLFD TXH SHUPLWH OD
FXUDFLyQGHODKHPRÀOLDPHGLDQWHODWUDQVIHUHQFLDGH
PDWHULDO JHQpWLFR DO SDFLHQWH D WUDYpV GH GLIHUHQWHV
PpWRGRVGHLQJHQLHUtDJHQpWLFD
DISCUSIÓN
/RV LQKLELGRUHV DSDUHFHQ FRQ XQD DOWD LQFLGHQFLD
HQ SDFLHQWHV FRQ +HPRÀOLD $ FRQJpQLWD KDVWD
XQ HQ SDFLHQWHV JUDYHV \ HQWUH HQ
SDFLHQWHVPRGHUDGRV\OHYHV7LHQGHQDDSDUHFHU
WUDVODVSULPHUDVDGPLQLVWUDFLRQHVGHFRQFHQWUDGR
GH)9,,,ORFXDOVXHOHFRLQFLGLUFRQORVSULPHURV
DxRV GH OD YLGD GHO SDFLHQWH $SUR[LPDGDPHQWH
XQ GH ORV QLxRV FRQ KHPRÀOLD JUDYH TXH
LQLFLDQWUDWDPLHQWRQRWROHUDQDOIDFWRUSHUIXQGLGR
/RV PHFDQLVPRV SRU ORV FXDOHV XQ GH ORV
KHPRItOLFRV WROHUDQ OD SURWHtQD SHUIXQGLGD FRQ
HO WUDWDPLHQWR QR VRQ ELHQ FRQRFLGRV 'DWR
FDUDFWHUtVWLFRGHELGRDTXHHOSDFLHQWHHQHVWXGLR
GXUDQWH PXFKRV DxRV PRVWUy EXHQD UHVSXHVWD DO
WUDWDPLHQWR FRQ )9,,, \ IXH KDVWD OD HGDG GH ORV
DxRVTXHPRVWUyWROHUDQFLDDGLFKRWUDWDPLHQWR
SRU OR TXH VH REVHUYD TXH ORV SDFLHQWHV SXHGHQ
GHVDUUROODU LQKLELGRUHV HQ FXDOTXLHU HWDSD GH OD
YLGD DXQTXH VHUtD GLItFLO LGHQWLÀFDU OD FDXVD GH
SRUTXpHOVLVWHPDLQPXQHGHVSXpVGHWDQWRVDxRV
GH WUDWDPLHQWR FRPHQ]y D UHDFFLRQDU \ DWDFDU HO
)9,,,SURWHtQDTXHKDEtDVLGRELHQWROHUDGDGXUDQWH
PXFKRVDxRV
$FWXDOPHQWH HO GHVDUUROOR GH DQWLFXHUSRV
LQKLELGRUHVFRQGLFLRQDQRVyORXQDGLVPLQXFLyQGH
Rev. Fac. Cienc. Méd. Julio - Diciembre 2010
Inhibidores Contra el Factor VIII de Coagulación en la Hemofilia Tipo A
ODFDOLGDGGHYLGDGHORVSDFLHQWHVVLQRTXHWDPELpQ
WLHQHLPSRUWDQWHVFRQVHFXHQFLDVVRFLRHFRQyPLFDV
GDGR HO LQFUHPHQWR HQ HO FRVWR GHO WUDWDPLHQWR
(Q ORV SDtVHV ODWLQRDPHULFDQRV H[LVWHQ PXFKRV
SUREOHPDV VRFLDOHV \ HFRQyPLFRV (Q PXFKRV GH
HVWRVSDtVHVREWHQHUSURGXFWRVSDUDHOWUDWDPLHQWR
GH ORV SDFLHQWHV FRQ LQKLELGRUHV GH )DFWRU 9,,,
HQ OD KHPRÀOLD 7LSR$ QR KD VLGR XQD SULRULGDG
UHVXOWDQGR HQ FDUHQFLD GH WUDWDPLHQWRV DGHFXDGRV
\JHQHUDQGRHQHVWRVVHULDVFRQVHFXHQFLDV(Q
+RQGXUDVVHFDUHFHQRVyORGHWUDWDPLHQWRDGHFXDGR
VL QR DGHPiV GH PpWRGRV ORV GLDJQyVWLFRV SDUD
LGHQWLÀFDUODVSHUVRQDVTXHKDQFUHDGRDQWLFXHUSRV
FRQWUD)DFWRU9,,,HVWRHVGHELGRDORVDOWRVFRVWRV
TXHUHSUHVHQWDQGLFKRVPDWHULDOHV3RUORTXHHVWRV
SDFLHQWHV HVWiQ FRQGHQDGRV DO VXIULPLHQWR \ D
SHUPDQHFHULQGHÀQLGDPHQWHKRVSLWDOL]DGRV
/D OLPLWDFLyQ H[FOX\HQWH SDUD WUDWDU HÀFD]PHQWH XQ
SDFLHQWH FRQ LQKLELGRU HV DFWXDOPHQWH OD VLWXDFLyQ
HFRQyPLFD(VSRUHOORTXHHOWUDWDPLHQWRGHSDFLHQWHV
FRQ LQKLELGRUHV GHEH UHDOL]DUVH HQIRFDQGR VX
WHUDSpXWLFDGHDFXHUGRFRQODUHDOLGDGGHFDGDSDtV\
FRQHOHPSOHRUDFLRQDOGHVXVUHFXUVRVWHUDSpXWLFRV
BIBLIOGRAFÍA
$UUXGD 9 +LJK . 7UDVWRUQRV GH OD
&RDJXODFLRQ,Q)DXFL$6.DVSHU'//RQJR
'/ %UDXQZDOG ( +DXVHU 6/ -DPHVRQ -/
/RVFDO]R - +DUULVRQ 3ULQFLSLRV GH 0HGLFLQD
,QWHUQDHG0H[LFR0F*UDZ+LOO
3
$VWHU -& (QIHUPHGDGHV GH ORV +HPDWtHV \
7UDVWRUQRV+HPRUUDJLFRV,Q.XPDU9$EEDV
$. )DXVWR 1 5RELQ \ &RWUDQ 3DWRORJLD
(VWXFWXUDO\)XQFLRQDOHG(VSDxD(OVHYLHU
3
)HGHUDFLyQ 0XQGLDO GH +HPRÀOLD 4XH VRQ
ORV ,QKLELGRUHV >0RQRJUDItD HQ LQWHUQHW@
&DQDGi)HGHUDFLyQ0XQGLDO+HPRÀOLD
>FRQVXOWDGR HO GH MXQLR @ 'LVSRQLEOH
HQ KWWSZZZZIKRUJGRFV3XEOLFDWLRQV ,QKLELWRUV,QKLELWRUVBERRNOHWB63SGI
/XQD*$5LYHUD3&$UHOODQR*-0HQGR]D
*0iUTXH]-/*RQ]iOH]$$HWDO0HGLFLyQ
GHODDFWLYLGDGGHIDFWRUHV9,,,\,;FRDJXODQWH
\ VXV SRVLEOHV LQKLELGRUHV HQ XQD SREODFLyQ
GH QLxRV KHPRItOLFRV %LRTXLPLD >5HYLVWD HQ
,QWHUQHW@ >&RQVXOWDGR HO GH PD\R
@ VXSO $ 'LVSRQLEOH HQ KWWS
UHGDO\FXDHPH[P[SGISGI
$]QDU -$ 9LOODU $ ,QKLELGRUHV DQWL
),,, +DHPDWRORJLFD HG HVS >(Q OtQHD@
>&RQVXOWDGR HO GH PD\R @ VXSO 'LVSRQLEOH HQ KWWSZZZVHWKHV
SRQHQFLDVVLPSRVLRVLQKLELGRUHVBDQWLB
IYLLLSGI
%LDQFR 53 2]HOR 0& 9LOODoD 35 6RODQR
0+&UX]*-0XULOOR&0HWDO'LDJQyVWLFR
\ WUDWDPLHQWR GH OD KHPRÀOLD FRQJpQLWD FRQ
LQKLELGRUHV 8Q FRQVHQVR ODWLQRDPHULFDQR
>(Q OtQHD@ >&RQVXOWDGR GH PD\R @
'LVSRQLEOHHQKWWSZZZDVKHFRYDRUJSKSB
OLEDUFKLYRBGHVFDUJDUSKS"GRFBLG 2FKRD 0$ 'HWHFFLyQ GH ,QKLELGRUHV
HQ SDFLHQWHV FRQ +HPRÀOLD +HUHGLWDULD
>7HVLV HQ LQWHUQHW@ 0p[LFR 3URJUDPD
GH (VSHFLDOLGDG HQ +HPDWRORJtD >&RQVXOWDGRHOGHPD\R@'LVSRQLEOH
HQ
KWWSLW]DPQDEQFWLSQP[
G V S D F H E L W V W UH D P '(7(&&,21,1+,%SGI
'L0LFKHOH '0 ,QKLELGRUHV HQ KHPRÀOLD
LQIRUPDFLyQEiVLFD>0RQRJUDIuDHQ,QWHUQHW@
&DQDGi)HGHUDFLyQ0XQGLDOGHOD+HPRÀOLD
>&RQVXOWDGR HO GH GLFLHPEUH @
'LVSRQLEOH HQ KWWSZZZZIK
RUJGRFV3XEOLFDWLRQV,QKLELWRUV72+B
,QKLELWRUVB63SGI
$UDQGD + $YDQFHV HQ HO WUDWDPLHQWR GH OD
KHPRÀOLD 5HY 0HG ,QVW 0H[ 6HJXUR 6RF
>5HYLVWD HQ ,QWHUQHW@ >&RQVXOWDGR HO
GH PD\R @ 6XSO 'LVSRQLEOH HQ KWWSQHZPHGLJUDSKLFFRP
FJLELQUHVXPHQ0DLQFJL",'$57,&8/2
,'38%/,&$&,21 ,'5(9,6
7$ Rev. Fac. Cienc. Méd. Julio - Diciembre 2010
Inhibidores Contra el Factor VIII de Coagulación en la Hemofilia Tipo A
+DXVO & $KPDG 58 6DVJDU\ 0 'RHULQJ
&% /ROODU 3 HW DO +LJKGRVH IDFWRU 9,,,
LQKLELWV IDFWRU 9,,,VSHFLÀF PHPRU\ % FHOOV
LQ KHPRSKLOLD $ ZLWK IDFWRU 9,,, LQKLELWRUV
%ORRG>5HYLVWDHQ,QWHUQHW@>&RQVXOWDGR
HO GH $EULO @ 'LVSRQLEOH HQ KWWSZZZQFELQOPQLKJRY
SXEPHG
3HHUOLQFN . -DFTXHPLQ 0* $UQRXW -
+R\ODHUWV 0) *LOOHV -* /DYHQG·KRPPH
5 HW DO$QWLIDFWRU 9,,, DQWLERG\ LQKLELWLQJ
DOORJHQHLF EXW QRW DXWRORJRXV IDFWRU 9,,,
LQ SDWLHQWV ZLWK PLOG KHPRSKLOLD $ %ORRG
>5HYLVWD HQ ,QWHUQHW@ >&RQVXOWDGR
HO GH $EULO @ 'LVSRQLEOH HQ KWWSZZZQFELQOPQLKJRY
SXEPHG
6DHQNRW(/6KLPD0*LOEHUW*(6FDQGHOOD
' 6ORZHG UHOHDVH RI WKURPELQFOHDYHG
IDFWRU 9,,, IURP YRQ :LOOHEUDQG IDFWRU E\ D
PRQRFORQDODQGDKXPDQDQWLERG\LVDQRYHO
PHFKDQLVP IRU IDFWRU 9,,, LQKLELWLRQ - %LRO
&KHP>5HYLVWDHQ,QWHUQHW@
>&RQVXOWDGR HO GH $EULO @ 'LVSRQLEOH HQ KWWSZZZQFELQOPQLKJRY
SXEPHG
Rev. Fac. Cienc. Méd. Julio - Diciembre 2010